Artemisinin-Naphthoquine Combination ARCO®: An Overview of the ProgressReportar como inadecuado




Artemisinin-Naphthoquine Combination ARCO®: An Overview of the Progress - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Centre for Health Research, Divine Word University, P O Box 483, Madang 555, Madang Province, Papua New Guinea

2

Medical Research Institute, Kunming Pharma, West suburb, Xishan Region, Kunming, China





*

Author to whom correspondence should be addressed.



Abstract With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose or a 1-day treatment. Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria. View Full-Text

Keywords: artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum





Autor: Francis W. Hombhanje 1,* and Qingyun Huang 2

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados